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Background: Bifidobacteria constitute a specific group of commensal bacteria that commonly inhabit the
mammalian gastrointestinal tract. Bifidobacterium breve UCC2003 was previously shown to utilize a variety of
plant/diet/host-derived carbohydrates, including cellodextrin, starch and galactan, as well as the mucin and
HMO-derived monosaccharide, sialic acid. In the current study, we investigated the ability of this strain to utilize
parts of a host-derived source of carbohydrate, namely the mucin glycoprotein, when grown in co-culture with
the mucin-degrading Bifidobacterium bifidum PRL2010.
Results: B. breve UCC2003 was shown to exhibit growth properties in a mucin-based medium, but only when
grown in the presence of B. bifidum PRL2010, which is known to metabolize mucin. A combination of HPAEC-PAD
and transcriptome analyses identified some of the possible monosaccharides and oligosaccharides which support
this enhanced co-cultivation growth/viability phenotype.
Conclusion: This study describes the potential existence of a gut commensal relationship between two
bifidobacterial species. We demonstrate the in vitro ability of B. breve UCC2003 to cross-feed on sugars released by
the mucin-degrading activity of B. bifidum PRL2010, thus advancing our knowledge on the metabolic adaptability
which allows the former strain to colonize the (infant) gut by its extensive metabolic abilities to (co-)utilize available
carbohydrate sources.
Keywords: Bifidobacteria, Probiotic, Fucose, Sialic acid, GalactoseBackground
Bifidobacteria are Gram positive, anaerobic, Y-shaped
bacteria that have been found in the gastrointestinal
tract (GIT) of mammals, birds and insects and have also
been isolated from the human oral cavity and sewage
[1]. In recent years, bifidobacteria have attracted atten-
tion due to the purported health benefits associated with
their presence in the gut. Such beneficial contributions
include development and modulation of the immune
system [2], provision of vitamins [3], and protection
against pathogenic bacteria [4]. Bifidobacteria rapidly
colonize the infant gut in the first days and weeks of life.* Correspondence: d.vansinderen@ucc.ie
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unless otherwise stated.In a recent study on the microbial diversity of the infant
gut, it was found that members of the Actinobacteria
phylum were dominant, with various bifidobacterial spe-
cies present in high abundance, in particular Bifidobacter-
ium longum, Bifidobacterium bifidum, Bifidobacterium
breve and Bifidobacterium catenulatum [5].
Survival and growth of bifidobacteria in the gastrointes-
tinal tract requires them to employ an arsenal of enzymes
to metabolize the complex carbohydrates prevalent in
this environment [6]. B. breve UCC2003 has previously
been shown to utilize various diet/plant-derived oligo-
and poly-saccharides, including melezitose, raffinose, cel-
lodextrins, GOS, starch and galactan [7-12]. Recently, B.
breve UCC2003 was shown to utilize the mucin- and hu-
man milk oligosaccharide (HMO)-derived monosacchar-
ide sialic acid [13], which is more consistent with thisd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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infant, where it would be expected to metabolize HMOs
and/or the structurally similar oligosaccharides found in
mucin glycoproteins. Along with dietary components,
host-derived oligosaccharides are believed to form part of
the nutrient resource for certain intestinal bacteria.
The original investigations on the (bio)chemical com-
position of human colonic mucin described twenty-one
discrete oligosaccharide structures [14]. Since then, it has
been estimated that carbohydrate constitutes approxi-
mately 80% of the total mucin mass, and that MUC2, the
prominent secretory mucin in the colon, may contain
more than 100 different O-linked glycans [15,16]. Glyco-
sylation of the peptide backbone can be N-linked to an
asparagine residue or O-linked to serine or threonine res-
idues via N-acetylgalactosamine (GalNAc). Subsequent
elongation of this structure results in a number of dis-
tinct core structures. While eight mucin type core struc-
tures are known, only four regularly occur in human
mucins. Core 1 is formed by the addition of galactose
(Gal) in a β-(1,3) linkage to GalNAc to produce galacto-
N-biose (GNB, also known as the T antigen). Core 3, the
most common core structure in the human colon, is
formed by the addition of N-acetylglucosamine (GlcNAc)
in a β-(1,3) linkage to GalNAc. Core 2 and core 4 struc-
tures are formed by the addition of GlcNAc in a β-(1,6)
linkage to core 1 and core 3, respectively. Each of the
core structures can be further elongated by the addition of
Gal, GalNAc and GlcNAc. The oligosaccharide chains can
also be substituted with sialic acid, fucose (Fuc) or sulfate
residues in terminal or branched positions [14,15,17,18].
Due to the high complexity and variability of the mucin
oligosaccharide chains, only a small proportion of the
culturable intestinal microbiota is believed to encode en-
zymes required for (partial) degradation of mucin into
free sugars. These include members of the Bifidobacter-
ium, Bacteroides and Ruminococcus genera, as well as a
more recently characterized bacterium isolated from hu-
man faeces, Akkermansia muciniphila [19,20]. The deg-
radation of mucin occurs sequentially with the removal of
component monosaccharides, rather than the removal
of the entire polysaccharide structure, thus requiring
a multitude of enzymes with various glycosidic spe-
cificities [21].
The first observation of mucin-degrading bifidobac-
teria was described by Hoskins et al., who described the
isolation of two bifidobacterial strains that constitutively
expressed extracellular enzymes capable of degrading
oligosaccharide side chains of gut mucins [22]. Cell
surface-anchored glycosyl hydrolases were later charac-
terized, including two α-L-fucosidases, AfcA and AfcB,
from B. bifidum JCM1254 [23,24], and an endo-α-N-acet-
ylgalactosaminidase, EngBF, from B. longum JCM1217,
which hydrolyzes the linkage between GalNAc of the core1 disaccharide and the serine or threonine residue of the
proteinaceous backbone [25].
As mentioned previously, B. bifidum is one of the most
abundant species in the infant intestine [5]. A study in
2010 revealed that some 60% of the glycosyl hydrolases
identified on the genome of B. bifidum PRL2010 are
linked to the degradation of mucin [26,27]. The identi-
fied glycosyl hydrolases include two putative exo-
α-sialidases, two putative α-L-fucosidases and a cell
wall-anchored endo-α-N-acetylgalactosaminidase [26].
Other mucin-degrading enzymes on the genome of B.
bifidum PRL2010 include four N-acetyl-β-hexosamini-
dases and four β-galactosidases [26,27]. Comparative
genome hybridization analysis revealed that most of
these genes encoding the above mentioned enzymes
are conserved within the examined members of the B.
bifidum species [26,27].
It has been suggested that the degradation of mucin by
a small number of extracellular glycosidase-producing
bacteria may provide nutritional support to other enteric
bacteria [22]. A similar concept was more recently sug-
gested in relation to the metabolism of HMO [28] and it
has been shown that a number of HMO-derived degrad-
ation products remain in the media during vegetative
growth of B. bifidum [29]. We recently demonstrated
that B. breve UCC2003 can indeed cross-feed on sialic
acid derived from the metabolism of 3′ sialyllactose, an
abundant HMO, by B. bifidum PRL2010 [13]. The aim of
the current study was to establish if B. breve UCC2003 is
able to cross-feed on the oligosaccharides released by B.
bifidum PRL2010 extracellular activity on mucin, and
secondly, to investigate which, if any, particular compo-
nents of mucin B. breve UCC2003 utilizes under such
circumstances.
Methods
Bacterial strains, plasmids, media and culture conditions
Bacterial strains and plasmids used in this study are listed
in Table 1. B. breve UCC2003 and its derivatives were
routinely cultured in Reinforced Clostridial Medium
(RCM; Oxoid Ltd, Basingstoke, Hampshire, United Kingdom).
B. bifidum PRL2010 was routinely cultured in modified
deMan Rogosa Sharpe (mMRS) medium made from
first principles (but excluding a carbohydrate source)
[30], and supplemented with 0.05% (wt/vol) L-cysteine
HCl and 1% (wt/vol) lactose (unless otherwise stated). All
carbohydrates used in this study were purchased from
Sigma Aldrich and were of the highest purity available. To
prepare mucin-containing media, a 0.8% (wt/vol) concen-
tration of mucin from porcine stomach (Type III) was
prepared in water and autoclaved at 115°C for 10 minutes,
in order to optimize mucin dissolution, yet minimiz-
ing glycosidic hydrolysis. This was added to an equal
volume of twice-concentrated mMRS, resulting in a
Table 1 Bacterial strains and plasmids used in this study
Strains and plasmids Relevant features Reference or source
Strains
Escherichia coli strains
E.coli EC101 Cloning host; repA+ kmr [37]
E.coli EC101-pNZ-M.Bbrll + Bbr11 EC101 harboring a pNZ8048 derivative containing bbrllM and bbrlllM [39]
Bifidobacterium sp. strains
B. breve UCC2003 Isolate from a nursling stool [36]
B. breve UCC2003-pAM5 B. breve UCC2003 harboring pAM5 This study
B. breve UCC2003-nanA pORI19-Tet-nanA (Bbr_0168) insertion mutant of B. breve UCC2003 [13]
B. breve UCC2003-fucP pORI19-Tet-fucP (Bbr_1742) insertion mutant of B. breve UCC2003 This study
B. breve UCC2003-lnbP pORI19-Tet-lnbP (Bbr_1587) insertion mutant of B. breve UCC2003 This study
B. breve UCC2003-lacZ7 pORI19-Tet-lacZ7 (Bbr_1833) insertion mutant of B. breve UCC2003 This study
B. breve UCC2003-galT Tetr transposon mutant of B. breve UCC2003 [41]
B. bifidum PRL2010 Isolate from infant faeces [26]
B. bifidum PRL2010-pPKCM7 B. bifidum PRL2010 harboring pPKCM7 This study
Plasmids
pAM5 pBC1-puC19-Tcr [38]
pPKCM7 pblueCm harboring rep pCIBA089 [40]
pORI19 Emr, repA−, ori+, cloning vector [37]
pORI19-tetW-fucP Internal 400 bp fragment of fucP and tetW cloned in pORI19 This study
pORI19-tetW-lnbP Internal 479 bp fragment of lnbP and tetW cloned in pORI19 This study
pORI19-tetW-lacZ7 Internal 568 bp fragment of lacZ7 and tetW cloned in pORI19 This study
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fidobacterial cultures were incubated under anaerobic
conditions in a modular atmosphere-controlled system
(Davidson and Hardy, Belfast, Ireland) at 37°C. Escherichia
coli was cultured in Luria Bertani (LB) broth at 37°C with
agitation [31]. Where appropriate, growth media con-
tained tetracycline (Tet; 10 μg ml−1), chloramphenicol
(Cm; 5 μg ml−1 for E. coli, 2.5 μg ml−1 for B. bifidum),
erythromycin (Em; 100 μg ml−1) or kanamycin (Kan;
50 μg ml−1).
Nucleotide sequence analysis
Sequence data were obtained from the Artemis-
mediated genome annotations of B. breve UCC2003
[32,33]. Database searches were performed using non-
redundant sequences available at the National Centre for
Biotechnology Information internet site (http://www.
ncbi.nlm.nih.gov) using BLAST [34]. Sequence analysis
was performed using the Seqbuilder and Seqman pro-
grams of the DNASTAR software package (DNASTAR,
Madison, WI, USA).
DNA manipulations
Chromosomal DNA was isolated from B. breve UCC2003
as previously described [35]. Plasmid DNA was isolated
from E. coli, B. breve and B. bifidum using the RocheHigh Pure plasmid isolation kit (Roche Diagnostics,
Basel, Switzerland). An initial lysis step was performed
using 30 mg ml−1 of lysozyme for 30 min at 37°C prior to
plasmid isolation from bifidobacteria. Single stranded
oligonucleotide primers used in this study were synthe-
sized by Eurofins (Ebersberg, Germany) (Table 2). PCRs
were performed using Taq PCR master mix (Qiagen
GmbH, Hilden, Germany). PCR products were purified
using the Roche High Pure PCR purification kit (Roche
Diagnostics). Electroporation of plasmid DNA into E. coli
or bifidobacteria was performed as described previously
[31,36].
Construction of B. breve UCC2003 insertion mutants
An internal fragment of Bbr_1742, designated here as
fucP (400 base pairs (bp), representing codon numbers
137 through to 270 out of the 421 codons of fucP),
Bbr_1587, designated here as lnbP (479 bp, representing
codon numbers 108 through to 267 of the 751 codons of
lnbP) and Bbr_1833, designated here as lacZ7 (568 bp,
representing codon numbers 123 through 312 of the 699
codons of lacZ7), were amplified by PCR using B. breve
UCC2003 chromosomal DNA as a template and primer
pairs FucPF and FucPR, LnbPF and LnbPR and LacZ7F
and LacZ7R, respectively. The generated amplicons were
digested with HindIII and XbaI, and ligated to the
Table 2 Oligonucleotide primers used in this study
Purpose Primer Sequence
Cloning of 400 bp fragment of fucP (Bbr_1742) in pORI19 FucPF TAGCATAAGCTTGGCGAATCGTTCGTATCA
FucPR GATATCTCTAGAGCGCCCCAGTGCTTGAGC
Cloning of 479 bp fragment of lnbP (Bbr_1587) in pORI19 LnbPF TAGCATAAGCTTCACACAGGTATTGGGAGGTTG
LnbPR CTAGTCTCTAGAGTTGTAGGCGCCACCATCC
Cloning of 568 bp fragment of lacZ7 (Bbr_1833) in pORI19 LacZ7F TAGCATAAGCTTCCAGGCCAAGAACTCCAGTG
LacZ7R CATGATTCTAGACAGCTTGGGCAGGTTGAACG
Amplification of tetW TetWF TCAGCTGTCGACATGCTCATGTACGGTAAG
TetWR GCGACGGTCGACCATTACCTTCTGAAACATA
Confirmation of site-specific homologous recombination FucPconfirm TGTTCGCCATGTTCGTTATC
LnbPconfirm GATCACTCTGCATATGGACG
LacZ7confirm GTACCGACATCGACGCGTTC
Restriction sites incorporated into oligonucleotide primer sequences are indicated in italics.
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plasmid [37]. The ligation mixtures were introduced into
E. coli EC101 by electroporation and transformants were
selected on LB agar containing Em and supplemented
with 40 mg ml−1 X-Gal (5-bromo-4-chloro-3-indolyl-β-
D-galactopyranoside) and 1 mM IPTG (isopropyl-β-D-
galactopyranoside). The plasmid content of a number of
Emr transformants was screened by restriction analysis
and the integrity of positively identified clones was veri-
fied by sequencing. This was followed by subcloning of
the Tet antibiotic resistance cassette, tetW from pAM5
[38] as a SacI fragment into the unique SacI site present
on each pORI19 derivative. The orientation of the tetW
fragment in each of the resulting plasmids, pORI19-
tetW-fucP, pORI19-tetW-lnbP and pORI 19-tetW-lacZ7,
was verified by restriction analysis, followed by the in-
troduction of the plasmid by electroporation into the E.
coli EC101 pNZ-MBbrI-MBbrII strain to methylate the
plasmid constructs prior to introduction into B. breve
UCC2003 [39]. Methylation of the plasmids was con-
firmed by their observed resistance to PstI digestion [39].
The methylated plasmids, pORI19-tetW-fucP, pORI19-
tetW-lnbP and pORI19-tetW-lacZ7, were introduced
into B. breve UCC2003 by electroporation and trans-
formants were selected on Reinforced Clostridial Agar
(RCA) supplemented with Tet. Site-specific recombin-
ation in potential Tet-resistant mutant isolates was con-
firmed by colony PCR using primer combinations TetWF
and TetWR to confirm tetW gene integration, and the
primers FucPconfirm, LnbPconfirm and LacZ7confirm
(positioned upstream of the selected internal fragment of
fucP, lnbP and lacZ7, respectively) and TetWF to con-
firm integration at the correct chromosomal location.
Evaluation of B. breve UCC2003 growth on mucin
Growth of B. breve UCC2003 using mucin as the sole
carbon source was determined both independently andin co-culture with B. bifidum PRL2010. Plasmid-
containing derivatives of the wild type strains were used,
namely B. breve UCC2003-pAM5, which contains the
pAM5 plasmid and is therefore Tet resistant [38] and B.
bifidum PRL2010-pPKCM7, which contains the pPKCM7
plasmid and is Cm resistant [40]. Use of plasmid-
containing derivatives allowed for selection and enumer-
ation of either B. breve UCC2003 or B. bifidum PRL2010
colonies on RCA containing the appropriate antibiotic. All
B. breve UCC2003 mutant strains were also Tet resistant.
A 0.001% inoculum of a stationary phase culture of B.
breve UCC2003 strains (see Table 1; B. breve UCC2003-
pAM5, or the mutant strains, B. breve UCC2003-nanA
[13], B. breve UCC2003-fucP, B. breve UCC2003-lnbP, B.
breve UCC2003-lacZ7 or B. breve UCC2003-galT [41])
and/or a 0.01% inoculum of B. bifidum PRL2010-
pPKCM7, were added to mMRS medium supplemented
with 0.05% (wt/vol) L-cysteine HCl and 0.4% (wt/vol)
mucin (see above). Growth of the cultures was measured
over 72 h, with samples taken every 6 or 12 h. All sam-
ples collected were serially 10-fold diluted in sterile
Ringers solution and plated onto RCA supplemented
with 1% (wt/vol) lactose and the appropriate antibiotic.
Viable counts were determined by counting colonies on
agar plates using dilutions that yielded between 30 and
300 colony forming units (CFU).
Transcriptome analysis using B. breve UCC2003-based
microarrays
B. breve UCC2003-pAM5 was grown in mMRS medium
supplemented with 0.05% (wt/vol) L-cysteine HCl and
0.4% ribose to an OD600nm of 0.5 and then harvested by
centrifugation at 9,000 × g for 2 min at room temperature.
B. breve UCC2003-pAM5 grown in mucin in co-culture
with B. bifidum PRL2010-pPKCM7 (see above) was simi-
larly harvested after 30 h of growth. DNA microarrays
containing oligonucleotide primers representing each of
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UCC2003 were designed by and obtained from Agilent
Technologies (Palo Alto, CA, USA). Methods for cell dis-
ruption, RNA isolation, RNA quality control, comple-
mentary DNA (cDNA) synthesis and labelling were
performed as described previously [42]. Labelled cDNA
was hybridized using the Agilent Gene Expression
hybridization kit (part number 5188–5242) as described in
the Agilent Two-Color Microarray-Based Gene Expres-
sion Analysis (v4.0) manual (publication number G4140-
90050). Following hybridization, microarrays were washed
as described in the manual and scanned using Agilent’s
DNA microarray scanner G2565A. The scanning results
were converted to data files with Agilent’s Feature Ex-
traction software (version 9.5). DNA-microarray data
were processed as previously described [43-45]. Differen-
tial expression tests were performed with the Cyber-T
implementation of a variant of the t-test [46].
Analysis of the monosaccharide composition of
fermented and non-fermented mucin
Identification and quantification of the free monosac-
charides in non-fermented mMRS supplemented with
0.4% mucin and the media following 30 h fermentation
by B. bifidum PRL2010-pPKCM7 was performed ac-
cording to Dionex technical note 40 (http://www.dio-
nex.com/en-us/webdocs/5052-TN40-IC-Glycoprotein-
Monosaccharide-23May2012-LPN1632-01.pdf ) and as
previously described [47], using high performance anion
exchange chromatography with pulsed amperometric de-
tection (HPAEC-PAD). In brief, media was pelleted out,
sterilized through a 0.2 μm filter and then lyophilized
to dryness. The lyophilized powder was dissolved at
1 mg ml−1 in purified water. Dilutions were injected on
to a Dionex ICS 3000 system (Dionex, Sunnyvale, CA)
equipped with a CarboPac PA20 analytical column
(150 mm × 3 mm) with an Amino-trap column (30 mm ×
3 mm) and separated as previously described [48]. Result-
ing peaks were identified and quantified by comparison
to a standard curve with a mixture containing the com-
mon mammalian residues Fuc, glucosamine (GlcN),
galactosamine (GalN), Gal, glucose (Glc) and mannose
(Man). Samples were injected three times and the average
value is reported for the concentration. Samples were
then spiked with a known concentration of Fuc and Gal
standards and re-injected to confirm the identification of
these residues in the sample.
To further confirm the identity of Fuc in spent medium,
samples were labelled with 2-aminobenzamide (2-AB) ac-
cording to the published method [49]. The 2-AB labelled
samples were cleaned on Glycoclean S cartridges (Pro-
zyme) according to manufacturer’s instructions and vac-
uum centrifuged dry. Samples were analyzed by reverse
phase-high performance liquid chromatography (RP-HPLC) injected onto a Waters Alliance 2695 instrument
and separated on a Phenomenex Luna 3u C18(2)
(150 mm× 4.6 mm) column using previously described
conditions [50].
During co-culture experiments samples of cell free su-
pernatants were taken every 6 or 12 h to qualitatively
analyze the carbohydrate composition of the media by
HPAEC-PAD. Samples (25 μl aliquots) were separated on
a CarboPac PA1 analytical-exchange column (250 mm ×
4 mm) with a CarboPac PA1 guard column (50 mm ×
4 mm). Elution was performed at a constant flow-rate of
1.0 ml min−1 at 30°C using the following eluents for the
analysis (A) 200 mM NaOH, (B) 100 mM NaOH,
550 mM sodium acetate, and (C) purified water. The fol-
lowing linear gradient of sodium acetate was used with
100 mM NaOH: from 0 to 50 min, 0 mM; from 50 to
51 min, 16 mM; from 51 to 56 min, 100 mM; from 56 to
61 min, 0 mM. Eluate was monitored with a Dionex
ED40 detector in the PAD mode. The chromatogram of
non-fermented mucin was used to evaluate mucin
utilization by B. bifidum PRL2010-pPKCM7 and B. breve
UCC2003-pAM5, and the Chromeleon software v. 6.70
(Dionex Corporation) was used for the integration and
evaluation of the chromatograms obtained.
Microarray data accession number
The microarray data obtained in this study have been
deposited in NCBI’s Gene Expression Omnibus database
and are accessible through GEO series accession number
GSE59013.
Ethics statement
No animal or human subjects were involved in this
study.
Results
Growth of B. breve UCC2003 on mucin
Growth of B. breve UCC2003-pAM5 and B. bifidum
PRL2010-pPKCM7 in mMRS supplemented with 0.4%
(wt/vol) mucin, independently or in co-culture, was
measured by viable plate counts over 72 h. Monitoring
of growth in co-culture required the use of plasmid-
containing derivatives of the wild type strains. The plas-
mids used, pAM5 for B. breve UCC2003 or pPKCM7 for
B. bifidum PRL2010, conferred Tet or Cm resistance to
the respective strains, thus allowing selection and enu-
meration of each strain by viable plate count on RCA
containing the corresponding antibiotic. Both B. breve
UCC2003-pAM5 and B. bifidum PRL2010-pPKCM7
were also cultured in mMRS supplemented with 0.5%
lactose, a substrate on which both strains achieve a high
level of growth [51,52], and it was found that presence
of the plasmid did not impair growth of the strain on
this substrate (results not shown). A low inoculum of
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B. bifidum PRL2010-pPKCM7, respectively, was used to
allow the strains to undergo multiple generations of
growth. In the absence of an added carbohydrate, no
growth was observed for either B. breve UCC2003-pAM5
or B. bifidum PRL2010-pPKCM7 in mMRS medium (re-
sults not shown). As expected, the positive control, B.
bifidum PRL2010-pPKCM7, was capable of growth in
mucin-containing mMRS medium, from a low inoculum
of 104 CFU ml−1 it attained cell numbers of approxi-
mately 108 CFU ml−1 following 36 h of incubation [26]
(Figure 1). However, a notably different growth profile
was observed for B. breve UCC2003-pAM5 on this
medium. During the first 12 h of incubation in this
medium, B. breve UCC2003-pAM5 viable cell numbers
increased from 104 CFU ml−1 to almost 107 CFU ml−1,
followed by a decline in viable cells to below 104 CFU
ml−1 (Figure 1). HPAEC-PAD analysis (see below) re-
vealed the presence of contaminating monosaccharides,
namely Glc and Gal, in the non-fermented mucin prepar-
ation. It is unknown whether these carbohydrates were
released from partial degradation of the mucin during
autoclaving, despite efforts made to reduce such degrad-
ation (see above), or were present as contaminating
monosaccharides in the mucin preparation. Given that B.
breve UCC2003 can utilize both of these contaminants as
a sole carbon source [51], it is hypothesized that they are
responsible for the observed growth during the first 12 h
following inoculation. Once these carbon sources were
utilized, and as B. breve UCC2003-pAM5 apparently does
not have the required enzymes to degrade intact mucin, a
substantial drop in viable count was observed. Interest-
ingly, when B. bifidum PRL2010-pPKCM7 was included
as a potential carbohydrate-releasing bacterium in co-
culture with B. breve UCC2003-pAM5, an improvement
in growth and survival abilities of B. breve UCC2003-
pAM5 was observed. In co-culture, B. breve UCC2003-
pAM5 reached cell numbers of almost 108 CFU ml−1Figure 1 Individual and co-culture growth profiles of B. breve UCC200
experiments were performed in mMRS supplemented with 0.4% mucin fro
values of duplicate experiments. Error bars represent the standard deviationafter 24 h and maintained a viable count of over
106 CFU ml−1 after 72 h (Figure 1). This suggests that B.
breve UCC2003-pAM5 is cross-feeding on (some of) the
sugars released following mucin breakdown by B. bifi-
dum PRL2010-pPKCM7. The cell numbers of B. bifidum
PRL2010-pPKCM7 were moderately lower in co-culture
as compared to when the strain was grown independently
in this medium and this was attributed to the presence of
another acid-producing strain in the culture. However,
the growth profile of B. bifidum PRL2010-pPKCM7 in
co-culture followed a similar trend to that of the strain
growing individually, suggesting that the two strains do
not compete for limiting amounts of mucin-derived
carbohydrates.
Gene expression analysis using B. breve UCC2003 DNA
microarrays
In order to investigate how the transcriptome of B. breve
UCC2003-pAM5 is affected by growth in co-culture
with B. bifidum PRL2010-pPKCM7 in mucin-containing
mMRS, global gene expression was determined by
microarray analysis during growth of the strain in co-
culture and compared with gene expression when grown
on ribose as the sole carbon source. Ribose was con-
sidered an appropriate carbohydrate for comparative
transcriptome analysis as the genes involved in ribose
metabolism are unique to this sugar [53], thus making it
an ideal substrate for gene expression analysis on other
carbohydrates. It has previously been used as a reference
condition in several transcriptome studies in B. breve
UCC2003 [7,9,10,13,54]. Furthermore, as a pentose sugar,
ribose is suitable for gene expression analysis in mucin,
given that the monosaccharide components of mucin are
all hexose sugars (Glc, Gal, GalNAc, GlcNAc or Fuc), ex-
cept sialic acid which is a nine-carbon monosaccharide.
In the current study, gene expression was determined fol-
lowing 30 h growth in co-culture. This was to ensure that
any observed changes in the transcriptome of B. breve3-pAM5 and B. bifidum PRL2010-pPKCM7 in mucin. All growth
m porcine stomach for 72 h. The results presented are the mean
.
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co-culture with B. bifidum PRL2010-pPKCM7, as op-
posed to growth on free monosaccharides in the mucin
preparation which appeared to be responsible for the ini-
tial 12 h of growth of B. breve UCC2003-pAM5 in mucin
(see above). Analysis of DNA microarray data showed
that a number of stress-related genes were up-regulated,
which was attributed to the cells being in co-culture with
another bacterium or to the possibility that the cells had
entered the stationary phase. Nonetheless, the majority
of genes that were shown to be significantly up-regulated
(fold change >2.5, P < 0.001) in co-culture are predicted
to be involved in the transport and metabolism of car-
bohydrates. One such cluster, Bbr_1740-1742, is believed
to be involved in Fuc metabolism and includes genes
predicted to encode a dihydrodipicolinate synthase
(Bbr_1740), an enzyme which was previously shown to
be involved in Fuc metabolism in Campylobacter jejuni
[55], a hypothetical protein (Bbr_1741) and a Fuc per-
mease (fucP, Bbr_1742). Transcription of a predicted
β-galactosidase-encoding gene (Bbr_1833, designated
lacZ7) was also significantly increased, this enzyme is
possibly involved in the removal of Gal from mucin oli-
gosaccharides, suggesting that B. breve UCC2003 may
utilize one or more Gal-containing fractions of mucin.
The Bbr_1585-1590 cluster was also up-regulated during
growth in co-culture. Bbr_1585 encodes a predicted
UDP-Glc-4-epimerase, designated galE. Previously, UDP-
Glc-4-epimerase enzymes have been shown to be in-
volved in the Leloir pathway for Gal metabolism [56], as
well as the GNB/LNB pathway for the metabolism of (ga)
lacto-N-biose (GNB/LNB) derived from HMO or mucin
[57,58]. Bbr_1586 encodes a predicted N-acetylhexosa-
mine-1-kinase, designated nahK. In B. longum JCM 1217,
an N-acetylhexosamine-1-kinase, which shares 90% iden-
tity to NahK, was shown to have a role in the previously
mentioned GNB/LNB pathway [57]. Bbr_1587 encodes a
predicted LNB phosphorylase, designated lnbP, an enzyme
which is also involved in the GNB/LNB pathway [57-59].
The LnbP protein from B. breve UCC2003 shares 90%
identity with the previously characterized LnbP protein
from B. bifidum JCM 1254 [58]. Finally, as regards to this
upregulated cluster, Bbr_1588-1590 encode a predicted
ABC transport system, including two predicted permease
proteins (represented by Bbr_1588 and Bbr_1589), and a
solute binding protein (Bbr_1590), which shares 98% iden-
tity with the GNB/LNB-specific binding protein of B.
longum JCM1217 [60]. Bbr_1884 (designated galT2), en-
coding a predicted Gal-1-phosphate uridyltransferase, an-
other enzyme required for the Leloir pathway and the
GNB/LNB pathway [56-58], was also up-regulated when
B. breve UCC2003 was grown in mucin in co-culture with
B. bifidum PRL2010. Finally, two gene clusters previously
shown to be responsible for the transport and metabolismof sialic acid were significantly up-regulated under these
growth conditions (Bbr_0160-0171 and Bbr_1247-1248)
[13] (Table 3).
Analysis of the monosaccharide composition of
fermented and non-fermented mucin
HPAEC-PAD was used to quantitatively analyze the
carbohydrate profile of non-fermented mucin, compared
to the cell free supernatant (CFS) of B. bifidum
PRL2010-pPKCM7 grown in mucin for 30 h. Non-
fermented mucin was shown to contain 0.13 nmol mg−1
of free Gal and 3.96 nmol mg−1 of free Glc, both of
which support growth of B. breve UCC2003 [51], thus
presenting a plausible explanation for the initial increase
in B. breve UCC2003-pAM5 cell numbers during the
first 12 h of incubation in mucin-containing medium
(Table 4). However, after 30 h growth of B. bifidum
PRL2010-pPKCM7, the carbohydrate profile of the
medium was significantly altered. Glc was no longer de-
tected, indicating its uptake by B. bifidum PRL2010-
pPKCM7, but the amount of free Gal increased to
51.73 nmol mg−1, while 34.94 nmol mg−1 of free Fuc
was also detected, indicative of the extracellular glycosi-
dase activity of B. bifidum PRL2010-pPKCM7 (Table 4).
A consistent pattern was observed in regards to the
amount of Fuc and Gal released by B. bifidum PRL2010
activity. The presence of Fuc was further verified by
fluorescent labelling of the CFS samples and analysis by
RP-HPLC (Figure 2A). It was also confirmed that free
Fuc was absent in non-fermented mMRS supplemented
with 0.4% mucin, which indicated that its presence was a
result of B. bifidum PRL2010-pPKCM7 extracellular ac-
tivity (Figure 2A). To investigate whether these released
monosaccharides from mucin support the observed
growth and viability of B. breve UCC2003-pAM5 in
co-culture, the carbohydrate profile of the CFS of the co-
culture was compared to that of B. bifidum PRL2010-
pPKCM7 grown independently in mucin (hence any
difference observed could be attributed to the presence
of B. breve UCC2003-pAM5). The results support the hy-
pothesis that B. breve UCC2003-pAM5 is cross-feeding
on at least one carbohydrate released following degrad-
ation of mucin by B. bifidum PRL2010-pPKCM7. After
30 h Fuc was present in the carbohydrate profile of B.
bifidum PRL2010-pPKCM7, but absent (or at least below
the detection level) in that of the co-culture, indicative of
its uptake and utilization by B. breve UCC2003-pAM5
(Figure 2B).
Growth of B. breve UCC2003 mutants in co-culture in
mucin with B. bifidum PRL2010-pPKCM7
HPAEC-PAD and transcriptome data suggested that the
improved growth and viability of B. breve UCC2003-
pAM5 in co-culture was a result of the strain cross-
Table 3 Effect of mucin (in co-culture with B. bifidum PRL2010) on the transcriptome of B. breve UCC2003
Gene No. Predicted Function Level of upregulation (P < 0.001)
Bbr_0161_nanK Conserved hypothetical protein in ROK family 4.22
Bbr_0162_nanE N-acetylmannosamine-6-phosphate 2-epimerase 5.46
Bbr_0164_nanB ABC transport system, solute binding protein 14.08
Bbr_0165_nanC ABC transport system, permease protein 11.82
Bbr_0166_nanD ABC transport system, ATP-binding protein 18.92
Bbr_0167_nanF ABC transport system, ATP-binding protein 22.14
Bbr_0168_nanA N-acetylneuraminate lyase 15.17
Bbr_0169_nagB1 Glucosamine-6-phosphate isomerase 17.77
Bbr_0171_nanH Sialidase 7.23
Bbr_0173_nanR Transcriptional regulator, GntR family 4.80
Bbr_1247_nagA2 N-acetylglucosamine-6-phosphate deacetylase 4.59
Bbr_1248_nagB3 Glucosamine-6-phosphate isomerase 6.08
Bbr_1585_galE UDP-Glc-4-epimerase 3.96
Bbr_1586_nahK N-acetylhexosamine kinase 3.67
Bbr_1587_lnbP Lacto-N-biose phosphorylase 3.19
Bbr_1588 ABC transport system, permease protein 3.34
Bbr_1589 ABC transport system, permease protein 2.88
Bbr_1590 ABC transport system, solute binding protein 8.95
Bbr_1740_dapA4 Dihydrodipicolinate synthase 9.91
Bbr_1741 Conserved hypothetical protein 8.83
Bbr_1742_fucP L-fucose permease 7.81
Bbr_1833_lacZ7 Beta-galactosidase 4.31
Bbr_1879 PTS system, glucose-specific IIABC component 6.97
Bbr_1880 PTS system, GlcNAc-specific IIBC component 18.15
Bbr_1884_galT2 Gal-1-phosphate uridylyltransferase 3.86
The cut-off point for the level of up-regulation is 2.5-fold with a P-value of <0.001.
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http://www.biomedcentral.com/1471-2180/14/282feeding on Fuc, while microarray data suggested sialic
acid, Gal, GNB and/or another of the Gal-containing
constituents of mucin may also be utilized. To deter-
mine which, if any, of these sugars was primarily respon-
sible for growth of the strain in co-culture, insertion
mutants were constructed in the fucP, lnbP and lacZ7
genes, resulting in strains B. breve UCC2003-fucP, B.
breve UCC2003-lnbP and B. breve UCC2003-lacZ7. Two
additional mutants, B. breve UCC2003-galT, which har-
bours a transposon in a predicted Gal-1-phosphate
uridyltransferase-encoding gene, designated galT1 and
was shown to be incapable of growth in Gal [41], and
the previously described insertion mutant, B. breveTable 4 Quantification of Fuc, Gal and Glc by HPAEC-PAD
Fuc Gal Glc
mMRS +0.4% mucin (non-fermented) n.d. 0.13 3.96
mMRS +0.4% mucin (30 h growth of
B. bifidum PRL2010)
34.94 51.73 n.d.
Concentrations given in nmol mg−1. n.d. = not detected.UCC2003-nanA, which cannot utilize sialic acid [13],
were also tested. The insertion mutants were individually
analyzed for their ability to grow in mucin in the pres-
ence or absence of B. bifidum PRL2010-pPKCM7. In the
absence of B. bifidum PRL2010-pPKCM7, the mutant
strains behaved similarly to B. breve UCC2003-pAM5, as
initial growth over the first 12 h was followed by a de-
cline in viable cells to 104 CFU ml−1 or lower at 72 h
(Figure 3). It was also found that removing the ability of
the strain to utilize a particular sugar did not sig-
nificantly affect its ability to grow in co-culture with
B. bifidum PRL2010-pPKCM7. Similar to B. breve
UCC2003-pAM5, all mutant strains attained a viable
count of between 107 and 108 CFU ml−1 between 12 h
and 30 h, and maintained a viable count of 106 CFU
ml−1 until 72 h, with the exception of B. breve
UCC2003-fucP which dropped to 105 CFU ml−1
(Figure 3). The carbohydrate profiles of each mutant
grown in co-culture were also analyzed by HPAEC-PAD
and it was found that each mutant, with the exception of
Figure 2 Analysis of the monosaccharide composition of fermented and non-fermented mucin. (A) HPLC profile of 2-AB -labelled (I) mMRS
supplemented with 0.4% mucin and (II) the media from (I) after 30 h growth of B. bifidum PRL2010-pPKCM7. The peak for Fuc is marked with *.
(B) Qualitative HPAEC-PAD analysis of (I) mMRS supplemented with 0.4% mucin, (II) the media from (I) following 30 h growth of B. bifidum
PRL2010-pPKCM7 and B. breve UCC2003-pAM5 in co-culture, (III) the media from (I) after 30 h growth of B. bifidum PRL2010-pPCM7. The peak for
Fuc is marked with *. nC, nanocoulombs.
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http://www.biomedcentral.com/1471-2180/14/282B. breve UCC2003-fucP, produced an identical carbo-
hydrate profile to that produced by the B. breve
UCC2003-pAM5. B. breve UCC2003-fucP, as expected,
was not capable of utilizing/transporting Fuc, as evident
from the presence of Fuc in its carbohydrate profile
(Figure 4).Discussion
Early investigations into the degradation of mucin estab-
lished the role of extracellular glycosidases produced by
a sub-population of bacteria in the gut, suggesting that
the remaining enteric bacteria may cross feed on the
released oligosaccharides [19,22]. Since then, much of
Figure 3 Individual and co-culture growth profiles of B. breve UCC2003 mutant strains in mucin. Growth profiles of the mutants (A) B.
breve UCC2003-nanA, (B) B. breve UCC2003-fucP, (C) B. breve UCC2003-lacZ7, (D) B. breve UCC2003-lnbP and (E) B. breve UCC2003-galT in mMRS
supplemented with 0.4% mucin, separately or in co-culture with B. bifidum PRL2010-pPKCM7, over 72 h. The results presented are the mean
values of duplicate experiments. Error bars represent standard deviation.
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http://www.biomedcentral.com/1471-2180/14/282the research into bacterial degradation of mucin has
focused on the characterization of such extracellular
glycosidases, such as two α-L-fucosidases and an exo-
α-sialidase from B. bifidum JCM1254, and an endo-
α-N-acetylgalactosaminidase from B. longum JCM1217
[23,24,61,62]. Another study identified, by a genomic as
well as a transcriptomic and proteomic approach, a
number of extracellular enzymes involved in mucin deg-
radation by B. bifidum PRL2010, including a predicted
cell wall-anchored endo-α-N-acetylgalactosamidase, twoα-L-fucosidases, two exo-α-sialidases, a β-galactosidase
and two putative N-acetyl-β-hexosaminidases, all of which
contained a signal peptide [26].
Extracellular enzymes similar to those outlined above
were not found in the genome of B. breve UCC2003
[33]. Therefore, it was not surprising that B. breve
UCC2003-pAM5 was incapable of high density growth
in a medium containing mucin as the sole carbon
source. However, when B. bifidum PRL2010-pPKCM7
was included as a co-cultivating, mucin-degrading
Figure 4 Analysis of the monosaccharide composition of
fermented and non-fermented mucin including B. breve
UCC2003-fucP. Qualitative HPAEC-PAD analysis of (I) mMRS
supplemented with 0.4% mucin, (II) the media from (I) following 36 h
growth of B. breve UCC2003-pAM5 and B. bifidum PRL2010-pPKCM7 in
co-culture, (III) the media from (I) following 36 h growth of B. bifidum
PRL2010-pPKCM7, (IV) the media from (I) following 36 h growth of B.
breve UCC2003-fucP and B. bifidum PRL2010-pPKCM7 in co-culture.
The peak for Fuc is marked with *. nC, nanocoulombs.
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http://www.biomedcentral.com/1471-2180/14/282bacterium, the growth and viability of B. breve
UCC2003-pAM5 was improved compared to the control
situation. A combination of HPAEC-PAD and transcrip-
tome analyses identified some of the possible monosac-
charides and oligosaccharides which could support this
enhanced co-cultivation growth/viability phenotype of B.
breve UCC2003-pAM5, represented by sialic acid, Fuc,
Gal and/or Gal-containing constituents of mucin.
HPAEC-PAD analysis identified two monosaccharides,
namely Fuc and Gal, which were released from mucin by
B. bifidum PRL2010-pPKCM7 activity. Fuc was shown to
be internalized by B. breve UCC2003-pAM5 during
growth in co-culture, suggesting a role in the enhanced
growth/viability phenotype of B. breve UCC2003-pAM5
in co-culture. Transcriptome and mutagenesis data sup-
ports this hypothesis, as shown by increased transcription
of a cluster (Bbr_1740-1742) involved in the uptake and
utilization of Fuc and by the inability of a mutant in the
fucP gene to internalize Fuc from the growth medium.
Gal has previously been shown to support the growth
of B. breve UCC2003 [51]. However, given that Gal is
ubiquitous in mucin, it may be internalized by B. breve
UCC2003-pAM5 as a monosaccharide and/or as a con-
stituent of a larger oligosaccharide. Interestingly, tran-
scriptome data revealed increased transcription of the
Bbr_1585-1590 gene cluster, which includes predicted
GalE, NahK and LnbP-encoding genes, all of which are
required for the metabolism of GNB [57], as well as an
adjacent predicted ABC transport system. Outside of this
cluster, the predicted galT2 gene (Bbr_1884) was also up-
regulated. A previous study in B. bifidum hypothesizedthat GalT2 is specifically required for the metabolism of
GNB from mucin [63]. Up-regulation of each of the re-
quired genes for the complete GNB pathway, as well as a
predicted transport system, suggests that GNB might be
the preferred source of Gal for B. breve UCC2003 in
co-culture. A predicted β-galactosidase-encoding gene,
lacZ7, was also up-regulated in co-culture, implying that
B. breve UCC2003 may utilize another Gal-containing
oligosaccharide. However, the precise substrate or pre-
ferred linkage of this enzyme is still a matter of specula-
tion. Gal-containing oligosaccharides and GNB were not
identified in the HPAEC-PAD data. However, the pres-
ence of four predicted β-galactosidases on the genome of
B. bifidum PRL2010, as well as a clear homolog of the
GNB pathway [26], suggests that B. bifidum PRL2010
also utilizes these sugars, and it is therefore possible that
in co-culture the two strains compete for such sugars.
Interestingly, transcriptome data also revealed in-
creased transcription of two clusters previously shown
to be up-regulated in the presence of sialic acid [13].
This is inconsistent with the HPAEC-PAD data, in which
sialic acid was not identified; however, it should be noted
that the mucin from porcine stomach used in this study
contains only 0.5%- 1.5% bound sialic acid, and it is thus
possible that the released sialic acid is below the detec-
tion level of the HPAEC-PAD system. However, since B.
bifidum PRL2010 has been shown to be incapable of
using sialic acid [13,26], it seems likely that B. breve
UCC2003 would utilize this sugar, even if available in
very low quantities.
While accepting the HPAEC-PAD and transcriptome
data are not definitive, the results suggest that B. breve
UCC2003-pAM5 utilizes a combination of sugars in co-
culture, a suggestion supported by the fact that none of
the mutants tested displayed a different phenotype to B.
breve UCC2003-pAM5 in co-culture. Construction of
double or triple mutant strains is expected to result in
strains that are impaired in growth/viability under co-
culture conditions, however, at present such multiple
mutant construction is not technically feasible for B.
breve UCC2003 (and have to the best of our knowledge
not been described for any bifidobacterial species/strain).
Our results highlight the different approaches taken by
two species of bifidobacteria to proliferate and survive in
the gut. B. bifidum PRL2010 has been shown to utilize
mucin oligosaccharides (and structurally similar HMOs),
a highly complex, yet ubiquitous carbohydrate source in
the gut. Aside from host glycans such as mucin and
HMO, however, the fermentation ability of B. bifidum
PRL2010 is rather limited [26,52]. B. breve UCC2003, on
the other hand, is a more versatile bacterium from a
metabolic perspective, capable of utilizing a number of
host and diet-derived carbohydrates. As seen in this
study it can scavenge constituents of mucin released by
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http://www.biomedcentral.com/1471-2180/14/282the extracellular glycosidase activity of other bifidobac-
teria, as well as cross-feed on certain HMO [13], a char-
acteristic which reflects the abundance of representatives
of this species in the infant gut [5]. However, B. breve
UCC2003 also has the ability to utilize a number of
plant-derived carbohydrates such as starch, galactan, cel-
lodextrins and raffinose [7,8,10,11]. B. breve strains have
been identified in the adult human bifidobacterial po-
pulation, although the relative abundance is lower than
in infants [5,64]. The similar phenotype of B. breve
UCC2003-pAM5 and the mutant strains in co-culture
also highlights the adaptability of the strain, emphasizing
its ability to switch to a different carbon source, depend-
ing on the carbohydrates available. This versatility is
reflected on the genome of B. breve UCC2003, which
contains a large number of carbohydrate utilization clus-
ters [33], suggesting an ability to alternate between and/
or co-utilize diet- and host- derived carbohydrates de-
pending on availability. The gut commensal Bacteroides
thetaiotaomicron, displays a remarkable metabolic flexi-
bility, whereby in the absence of a dietary-derived fibre,
this bacterium will shift its metabolic activities towards
the degradation of mucin [65]. These results suggest that
B. breve UCC2003 may also be capable of such flexibility,
although further study is required.
The ability to degrade mucin seems to be limited to
particular gut commensals, such as certain species of
Bacteroides, Bifidobacterium, Ruminococcus and Akker-
mansia [20,26,66-68]. Pathogenic bacteria appear to be
poorly adapted to mucin degradation [69], however,
multiple studies have shown pathogens utilizing constit-
uents of mucin released by commensal glycosidases. For
example, C. jejuni has been shown to utilize Fuc as a
substrate for growth [55], while enterohaemorrhagic E.
coli uses Fuc as a signal to induce virulence [70]. Simi-
larly, Salmonella typhimurium and Clostridium difficile
have been shown to utilize sialic acid released by the
sialidase activity of Bacteroides thetaotaomicron in a
gnotobiotic mouse [71]. The uptake of mucin-derived
Fuc by B. breve UCC2003, as well as the presumable
utilization of mucin-derived sialic acid, suggests a poten-
tial role for B. breve UCC2003 in “mopping up” the re-
leased constituents of mucin, providing competition to
potential pathogens and inhibiting or limiting their pro-
liferation, although further study is required to expand
on this hypothesis.
The mutually beneficial relationship between the host
and the intestinal bacteria has been well established [72],
however, it is of equal importance to acknowledge the
symbiotic relationships formed between genera and spe-
cies of the intestinal bacteria. Cross-feeding between B.
breve UCC2003 and B. bifidum PRL2010 has now been
shown for mucin in the present work and previously for
3′ sialyllactose [13], and given the structural similaritybetween mucin oligosaccharides and HMOs, it may be
assumed that B. breve UCC2003 has the ability to cross
feed on other HMO-derived constituents that are re-
leased by B. bifidum PRL2010. These results highlight
the compatibility of these two species of bifidobacteria,
especially when viewed in contrast to the strategy
employed by B. longum subsp. infantis, which assimilates
HMOs in their intact form, leaving none for potential
cross-feeding with another species [73]. Interestingly, an-
other type of cross-feeding has been described, whereby
Eubacterium halii utilizes lactate produced by Bifidobac-
terium adolescentis during growth on starch, resulting in
butyrate production by Eu. halii [74]. Butyrate is a major
source of energy for colonocytes and has also been im-
plicated in protection against colonic carcinogenesis
[75,76]. Understanding such complex interactions be-
tween different members of the intestinal bacteria is of
crucial importance when attempting to influence the ac-
tivity or composition of the intestinal microbiota, such as
in the use of probiotics.
Conclusion
This study provides in vitro proof for the existence of a
commensal relationship between two species of bifido-
bacteria in the large intestine, namely B. breve and B.
bifidum, in which B. breve UCC2003 benefits from the
carbohydrates released by the extracellular glycosidase
activities of B. bifidum PRL2010. To our knowledge, this
is the first study to describe the molecular details of
such cross-feeding, with particular emphasis on the
carbohydrate components which support the improved
growth and survival in co-culture. The results shown
here improve our knowledge on how B. breve UCC2003
colonizes the (infant) gut in the absence of dietary-
derived carbohydrates, and also emphasize this strain’s
ability to switch between carbohydrate sources depend-
ing on availability. This is an advantageous characteristic
in terms of enhanced survival and colonization ability in
both the infant and adult gut, and may present an ad-
vantage to the host in limiting opportunities for patho-
genic microbes to proliferate in the gut.
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